NEW YORK, Oct. 24, 2017 /PRNewswire/ --
Antares Pharma, Inc. (ATRS)
Lifshitz & Miller announces an investigation on
behalf of ATRS investors concerning whether ATRS issued false and misleading statements about its lead product XYOSTED.
If you are an ATRS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780
or e-mail at info@jlclasslaw.com.
CenturyLink, Inc. (CTL)
Lifshitz & Miller announces an investigation on
behalf of CTL investors concerning whether CTL issued false and misleading statements and/or failed to disclose that its policies
allowed CTL employees to add services or lines to accounts without customer permission, resulting in millions of unauthorized
charges to customers.
If you are a CTL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at
(516)493-9780 or e-mail at info@jlclasslaw.com.
CytRx Corporation (CYTR)
Lifshitz & Miller announces an investigation on
behalf of CYTR investors concerning whether CYTR issued false and misleading statements about its phase 3 clinical trial of
aldoxorubicin. Specifically, on August 14, 2017, the U.S. District Court for the Central
District of California denied, in part, CYTR's motion to dismiss a putative class action against
CYTR, among others.
If you are a CYTR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or
e-mail at info@jlclasslaw.com.
Dentsply Sirona, Inc. (XRAY)
Lifshitz & Miller announces an investigation on
behalf of XRAY investors after XRAY announced the abrupt resignations of its CEP, COO and Executive Chairman on October 2, 2017.
If you are an XRAY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780
or e-mail at info@jlclasslaw.com.
Dr. Reddy's Laboratories Limited (RDY)
Lifshitz & Miller announces an investigation on
behalf of RDY investors concerning whether RDY lacked an effective corporate quality system after RDY received a warning letter
from the FDA.
If you are an RDY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at
(516)493-9780 or e-mail at info@jlclasslaw.com.
J.Jill, Inc. (JILL)
Lifshitz & Miller announces an investigation on
behalf of JILL investors concerning whether JILL issued false and misleading statements about its purportedly unique sales and
marketing approach to insulate JILL from adverse trends affecting the retail industry.
If you are a JILL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780
or e-mail at info@jlclasslaw.com.
Navient Corporation (NAVI)
Lifshitz & Miller announces an investigation on
behalf of NAVI investors concerning whether NAVI had adequate internal controls to prevent alleged accounting violations and
misconduct in servicing student loans.
If you are a NAVI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780
or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING. © 2017 Lifshitz & Miller LLP. The law firm responsible for this
advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New
York 11530, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any
future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz & Miller LLP
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@jlclasslaw.com
View original content:http://www.prnewswire.com/news-releases/lifshitz--miller-llp-announces-investigation-of-antares-pharma-inc-centurylink-inc-cytrx-corporation-dentsply-sirona-inc-dr-reddys-laboratories-limited-jjill-inc-and-navient-corporation-300542571.html
SOURCE Lifshitz & Miller Law Firm